S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:APLS

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

$54.77
-1.96 (-3.45%)
(As of 02/3/2023 09:03 PM ET)
Add
Compare
Today's Range
$54.76
▼
$56.95
50-Day Range
$46.59
▼
$56.73
52-Week Range
$33.32
▼
$70.00
Volume
1.31 million shs
Average Volume
1.25 million shs
Market Capitalization
$6.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$71.23

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.62 Rating Score
Upside/​Downside
30.1% Upside
$71.23 Price Target
Short Interest
Bearish
8.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.74mentions of Apellis Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$4.28 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.28) to ($4.95) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

266th out of 1,025 stocks

Pharmaceutical Preparations Industry

125th out of 498 stocks

See Top Rated MarketRank™ Stocks Here
APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

February 3, 2023 | americanbankingnews.com
Apellis Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:APLS)
February 1, 2023 | americanbankingnews.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $46,587.08 in Stock
February 6, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 28, 2023 | americanbankingnews.com
Karen Lewis Sells 2,955 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock
December 16, 2022 | finance.yahoo.com
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
December 7, 2022 | finance.yahoo.com
Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?
November 29, 2022 | barrons.com
Premarket Movers: Elbit Systems, CME Group Cl A, Apellis Pharmaceuticals
November 18, 2022 | benzinga.com
Looking At Apellis Pharmaceuticals's Recent Unusual Options Activity
February 6, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
November 18, 2022 | marketwatch.com
Apellis Shares Jump Premarket as FDA Accepts Amendment >APLS
November 18, 2022 | markets.businessinsider.com
Apellis : FDA Accepts Pegcetacoplan NDA Amendment For Geographic Atrophy; Stock Up
November 18, 2022 | finance.yahoo.com
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
November 8, 2022 | markets.businessinsider.com
5 Analysts Have This to Say About Apellis Pharmaceuticals
October 16, 2022 | seekingalpha.com
Citi lists four more value-creating events in biotech for this year
October 12, 2022 | finance.yahoo.com
Corcept (CORT) Begins Phase II Study on Dazucorilant for ALS
October 3, 2022 | finance.yahoo.com
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
September 8, 2022 | markets.businessinsider.com
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
September 7, 2022 | seekingalpha.com
Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
September 1, 2022 | finance.yahoo.com
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years
August 24, 2022 | msn.com
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
August 24, 2022 | seekingalpha.com
Apellis stock rises as 2-year data of pegcetacoplan for eye disorder shows promise
August 24, 2022 | finance.yahoo.com
Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)
August 8, 2022 | seekingalpha.com
Apellis Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
August 8, 2022 | seekingalpha.com
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call Transcript
August 8, 2022 | finance.yahoo.com
Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results
July 19, 2022 | msn.com
Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review
July 19, 2022 | finance.yahoo.com
Apellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for Review
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
11/08/2021
Today
2/06/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
CUSIP
N/A
CIK
1492422
Web
www.apellis.com
Phone
(617) 977-5700
Fax
N/A
Employees
476
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$71.23
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+30.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.62
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-746,350,000.00
Net Margins
-560.92%
Pretax Margin
-558.72%
Return on Equity
-194.70%
Return on Assets
-64.99%

Debt

Debt-to-Equity Ratio
0.30
Current Ratio
7.21
Quick Ratio
6.69

Sales & Book Value

Annual Sales
$113.05 million
Price / Sales
53.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.04 per share
Price / Book
26.85

Miscellaneous

Outstanding Shares
110,576,000
Free Float
101,730,000
Market Cap
$6.06 billion
Optionable
Not Optionable
Beta
1.20

Key Executives

  • Cedric FrancoisCedric Francois
    President, Chief Executive Officer & Director
  • Timothy Eugene Sullivan
    Chief Financial Officer & Treasurer
  • Pascal DeschateletsPascal Deschatelets
    Chief Scientific Officer
  • Nur Nicholson
    Chief Technical Operations Officer
  • Caroline Baumal
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

13 brokerages have issued 12 month price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $123.00. On average, they predict the company's stock price to reach $71.23 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the start of the year. Since then, APLS shares have increased by 5.9% and is now trading at $54.77.
View the best growth stocks for 2023 here.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our APLS earnings forecast.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) issued its earnings results on Monday, November, 7th. The company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.48) by $0.27. The firm had revenue of $22.06 million for the quarter, compared to analysts' expectations of $19.82 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 194.70% and a negative net margin of 560.92%.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI acted as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.66%), Allspring Global Investments Holdings LLC (0.11%), New York State Common Retirement Fund (0.09%), Bank of Montreal Can (0.09%), Comerica Bank (0.06%) and State of New Jersey Common Pension Fund D (0.05%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown.
View institutional ownership trends.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $54.77.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $6.06 billion and generates $113.05 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 476 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 2/6/2023 by MarketBeat.com Staff